Enteris BioPharma\'s "Feasibility-to-Licensing" Partner\, Cara Therapeutics\, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis